Skip to main content
Premium Trial:

Request an Annual Quote

BioVision Sells ImVision Spin-Off to Swiss Investment Shop

NEW YORK, May 3 (GenomeWeb News) - Germany-based peptide-identification company BioVision has sold its ImVision spin-off to Swiss life-science investment company Nextech, the company said today.


ImVision develops immunotherapeutics based on its Modular-Antigen-Transport technology to treat allergic diseases, infectious diseases, and "possibly" cancer. The technology was developed by BioVision and the Swiss Institute of Allergy and Asthma Research.


As a biological research organization, BioVision offers "mainly" services for peptide biomarker discovery "but pursues also selected in-house research projects," BioVision Chief Business Officer Rainer Voegeli said in a statement. "It is the policy of BioVision to partner or to sell projects which have reached development status. ImVision is the first, others will follow."


Financial terms of the sale were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.